Biogen stock popped in relief Friday after the biotech company scrapped several tests in Alzheimer's treatment for a drug known as elenbecestat. It was being developed with Japan's Eisai.

source https://finance.yahoo.com/m/2c41db4b-55b1-3331-a2cb-10cf01e5b269/biogen-scraps-2-more-studies.html?.tsrc=rss